
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5456324/publications.pdf Version: 2024-02-01



Δνισφζεί Ι Βιισλι

#	Article	IF	CITATIONS
1	Impact of COVIDâ€19 pandemic on acute heart failure admissions and mortality: a multicentre study (COVâ€HFâ€SIRIO 6 study). ESC Heart Failure, 2022, 9, 721-728.	3.1	20
2	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 336-349.	1.0	2
3	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	27.0	1,080
4	Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. Journal of the American Heart Association, 2021, 10, e018176.	3.7	14
5	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 28-33.	4.0	2
6	Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart, 2021, 107, 1739-1747.	2.9	18
7	Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice. Postepy W Kardiologii Interwencyjnej, 2021, 17, 141-154.	0.2	2
8	Chronotropic Incompetence Limits Aerobic Exercise Capacity in Patients Taking Beta-Blockers: Real-Life Observation of Consecutive Patients. Healthcare (Switzerland), 2021, 9, 212.	2.0	7
9	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	3.7	17
10	The Impact of Using a Larger Forearm Artery for Percutaneous Coronary Interventions on Hand Strength: A Randomized Controlled Trial. Journal of Clinical Medicine, 2021, 10, 1099.	2.4	4
11	Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal, 2021, 233, 92-101.	2.7	7
12	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
13	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation, 2021, 143, 2129-2142.	1.6	101
14	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiology Journal, 2021, 28, 607-614.	1.2	3
15	Combined use of stress echocardiography and cardiopulmonary exercise testing to assess exercise intolerance in patients treated for acute myocardial infarction. PLoS ONE, 2021, 16, e0255682.	2.5	4
16	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiology, 2021, 6, 1440.	6.1	43
17	Mechanisms of Exercise Capacity Improvement after Cardiac Rehabilitation Following Myocardial Infarction Assessed with Combined Stress Echocardiography and Cardiopulmonary Exercise Testing. Journal of Clinical Medicine, 2021, 10, 4083.	2.4	3
18	Longâ€Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7

#	Article	IF	CITATIONS
19	Improvement of left ventricular function after percutaneous coronary intervention in patients with stable coronary artery disease and preserved ejection fraction: Impact of diabetes mellitus. Cardiology Journal, 2021, 28, 923-931.	1.2	4
20	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal, 2021, , .	1.2	3
21	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy. Scientific Reports, 2021, 11, 21390.	3.3	2
22	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	2.2	27
23	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 2020, 293, 35-41.	0.8	5
24	Assessment of quality of care of patients with ST-segment elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 893-901.	1.0	5
25	Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity. Scientific Reports, 2020, 10, 16682.	3.3	9
26	Impact of the Use of a Larger Forearm Artery on the Efficacy and Safety of Transradial and Transulnar Access: A Randomized Trial with Preprocedural Ultrasonography. Journal of Clinical Medicine, 2020, 9, 3607.	2.4	5
27	Younger age of patients with myocardial infarction is associated with a higher number of relatives with a history of premature atherosclerosis. BMC Cardiovascular Disorders, 2020, 20, 410.	1.7	8
28	Comparative Efficacy and Safety of Oral P2Y <sub>12</sub> Inhibitors in Acute Coronary Syndrome. Circulation, 2020, 142, 150-160.	1.6	93
29	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. American Heart Journal, 2020, 227, 56-63.	2.7	24
30	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. Thrombosis and Haemostasis, 2020, 120, 449-456.	3.4	10
31	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241
32	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <â€7% are associated with lower major cardiovascular events. American Heart Journal, 2020, 225, 97-107.	2.7	5
33	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiology Journal, 2020, 27, 661-676.	1.2	7
34	TransRadial versus transUlnar artery approach for elective invasive percutaneous coronary interventions: a randomized trial on the feasibility and safety with ultrasonographic outcome – RAUL study. Postepy W Kardiologii Interwencyjnej, 2020, 16, 376-383.	0.2	0
35	Professor Leszek Ceremużyński (1932–2009): a prominent figure in Polish cardiology. Kardiologia Polska, 2020, 78, 263-264.	0.6	Ο
36	Cardiac tamponade as a complication of pancreaticopericardial fistula. Kardiologia Polska, 2020, 78, 932-933.	0.6	0

#	Article	IF	CITATIONS
37	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
38	Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTRolled ELECTRa registry: is female sex a predictor of complications?. Europace, 2019, 21, 1890-1899.	1.7	4
39	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
40	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 2019, 48, 563-569.	2.1	11
41	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. Circulation, 2019, 140, 1960-1963.	1.6	7
42	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	27.0	833
43	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y <sub>12</sub> Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. Journal of the American Heart Association, 2019, 8, e011139.	3.7	33
44	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. European Heart Journal, 2019, 40, 1728-1738.	2.2	8
45	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. American Heart Journal, 2019, 208, 65-73.	2.7	14
46	Smoking and cardiovascular diseases – is there more paradox than expected?. Polish Archives of Internal Medicine, 2019, 129, 700-706.	0.4	10
47	A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection. Vasa - European Journal of Vascular Medicine, 2019, 48, 181-184.	1.4	1
48	Significant left ventricular outflow tract obstruction observed during postexercise verticalization in a symptomatic patient with hypertrophic cardiomyopathy. Kardiologia Polska, 2019, 77, 655-656.	0.6	0
49	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 473.	6.1	33
50	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
51	Adiponectin gene variants and decreased adiponectin plasma levels are associated with the risk of myocardial infarction in young age. Gene, 2018, 642, 498-504.	2.2	14
52	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	13.7	628
53	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. American Journal of Cardiology, 2018, 121, 294-300.	1.6	6
54	Echocardiographic predictors of exercise intolerance in patients with heart failure with severely reduced ejection fraction. Medicine (United States), 2018, 97, e11523.	1.0	5

#	Article	IF	CITATIONS
55	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54. Journal of the American Heart Association, 2018, 7, e009260.	3.7	8
56	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	13.7	70
57	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	1.6	11
58	ESR2 gene G1730A variant is associated with triglycerides level and myocardial infarction in young men but not in women. Gene, 2018, 677, 83-88.	2.2	2
59	Response to "Acetazolamide and Cardiac Failureâ€, Clinical Drug Investigation, 2018, 38, 651-651.	2.2	1
60	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	27.0	205
61	Exercise left ventricular outflow tract obstruction as a cause of exercise intolerance: combined stress echocardiography and cardiopulmonary exercise testing. Kardiologia Polska, 2018, 76, 1492-1492.	0.6	3
62	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	2.7	36
63	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry, 2017, 63, 325-333.	3.2	97
64	Inflammatory Biomarkers Interleukinâ€6 and Câ€Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq0 0 0 rg	ʒBT <b>∄Ø</b> verlα	ock1 <b>79</b> Tf 50 3
65	Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study. Clinical Drug Investigation, 2017, 37, 1175-1181.	2.2	37
66	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. International Journal of Cardiology, 2017, 245, 271-276.	1.7	22
67	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	2.8	95
68	Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor. Kardiologia Polska, 2017, 75, 614-614.	0.6	1
69	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	1.7	8
70	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2016, 315, 1591.	7.4	190
71	Right ventricular systolic function as a marker of prognosis after ST-elevation inferior myocardial infarction 5-year follow-up. International Journal of Cardiology, 2016, 221, 549-553.	1.7	14
72	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 2016, 1, 425.	6.1	88

#	Article	IF	CITATIONS
73	Lipoproteinâ€Associated Phospholipase A <sub>2</sub> Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2016, 5, .	3.7	44
74	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. European Journal of Preventive Cardiology, 2016, 23, 839-846.	1.8	39
75	Bleeding and Quality of Lifea^—. Journal of the American College of Cardiology, 2016, 67, 66-68.	2.8	1
76	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y <sub>12</sub> inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 2016, 37, 1133-1142.	2.2	138
77	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	2.2	5,890
78	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
79	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. American Journal of Medicine, 2015, 128, 766-775.	1.5	81
80	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. European Heart Journal, 2015, 36, 976-983.	2.2	61
81	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. European Journal of Preventive Cardiology, 2015, 22, 771-778.	1.8	41
82	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. Heart, 2014, 100, 1456-1461.	2.9	3
83	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 2014, 370, 1702-1711.	27.0	467
84	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2014, 35, 1541-1550.	2.2	70
85	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American College of Cardiology, 2014, 63, 1493-1499.	2.8	47
86	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. American Heart Journal, 2014, 168, 96-102.e2.	2.7	17
87	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128, 237-243.	1.6	195
88	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2013, 166, 290-297.	2.7	20
89	Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume. JACC: Cardiovascular Interventions, 2013, 6, 258-266.	2.9	117
90	Cystatin C– and Creatinine-Based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study. Clinical Chemistry, 2013, 59, 1369-1375.	3.2	19

#	Article	IF	CITATIONS
91	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915
92	Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. European Heart Journal, 2013, 34, 993-1001.	2.2	35
93	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
94	Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non–ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study. Clinical Chemistry, 2012, 58, 190-199.	3.2	38
95	Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. European Heart Journal, 2012, 33, 51-60.	2.2	62
96	Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation. Journal of the American College of Cardiology, 2012, 60, 2490-2499.	2.8	349
97	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. Stroke, 2012, 43, 3291-3297.	2.0	83
98	Risk-Prediction Model for Ischemic Stroke in Patients Hospitalized With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE]). American Journal of Cardiology, 2012, 110, 628-635.	1.6	11
99	Right Ventricular Dysfunction and Exercise Capacity After Inferior (Posterior) Wall Acute Myocardial Infarction. American Journal of Cardiology, 2012, 110, 784-789.	1.6	9
100	Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients—Results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal, 2012, 164, 728-734.	2.7	8
101	Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 806-817.	27.0	2,207
102	Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal, 2011, 161, 254-260.e4.	2.7	46
103	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non–ST-elevation acute coronary syndromes. American Heart Journal, 2011, 161, 878-885.	2.7	8
104	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, The, 2011, 377, 1409-1420.	13.7	1,759
105	Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non–ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial). American Journal of Cardiology, 2011, 108, 1373-1381.	1.6	16
106	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal, 2011, 32, 581-589.	2.2	199
107	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal, 2011, 32, 2781-2789.	2.2	487
108	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2011, 32, 2933-2944.	2.2	335

#	Article	IF	CITATIONS
109	Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial. Kardiologia Polska, 2011, 69, 898-905.	0.6	11
110	The diagnostic and prognostic value of right ventricular myocardial velocities in inferior myocardial infarction treated with primary percutaneous intervention. Kardiologia Polska, 2011, 69, 1054-61.	0.6	5
111	A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: The GRACE Genetics Study. European Heart Journal, 2010, 31, 1132-1141.	2.2	50
112	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. JAMA - Journal of the American Medical Association, 2010, 304, 1339-1349.	7.4	161
113	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. European Heart Journal, 2010, 31, 2133-2140.	2.2	35
114	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. European Heart Journal, 2010, 31, 50-58.	2.2	81
115	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq1 1 0.78431 patients with coronary heart disease. American Heart Journal, 2010, 160, 655-661.e2.	4 rgBT /Ov 2.7	verlock 10 Tf 111
116	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	13.7	725
117	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation, 2010, 122, 1056-1067.	1.6	354
118	Reperfusion in Patients With Renal Dysfunction After Presentation With ST-Segment Elevation or Left Bundle Branch Block. JACC: Cardiovascular Interventions, 2009, 2, 26-33.	2.9	78
119	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk. American Heart Journal, 2009, 157, 502-508.	2.7	28
120	Validity of a risk-prediction tool for hospital mortality: The Global Registry of Acute Coronary Events. American Heart Journal, 2009, 157, 1097-1105.	2.7	77
121	The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. American Heart Journal, 2009, 158, 193-201.e5.	2.7	165
122	Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2009, 53, 1411-1421.	2.8	50
123	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	27.0	6,019
124	In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. The Global Registry of Acute Coronary Events. Revista Espanola De Cardiologia (English Ed ), 2009, 62, 501-509.	0.6	1
125	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. American Journal of Cardiology, 2008, 101, 919-924.	1.6	11
126	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2008, 30, 426-435.	2.2	192

#	Article	IF	CITATIONS
127	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. European Heart Journal, 2008, 30, 655-661.	2.2	149
128	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation, 2008, 118, 2038-2046.	1.6	98
129	Resistance to oral antiplatelet drugs–a Position Paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society. Kardiologia Polska, 2008, 66, 470-6, 480-5.	0.6	3
130	Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes <subtitle>The MERLIN-TIMI 36 Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2007, 297, 1775.	7.4	448
131	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006. JAMA - Journal of the American Medical Association, 2007, 297, 1892.	7.4	744
132	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. Circulation, 2007, 116, 2793-2801.	1.6	213
133	Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification. American Heart Journal, 2007, 153, 493-499.	2.7	15
134	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non–ST elevation acute coronary syndromes. American Heart Journal, 2007, 154, 71-78.	2.7	93
135	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal, 2007, 28, 1598-1660.	2.2	1,699
136	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2007, 50, 1742-1751.	2.8	253
137	Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2007, 100, 1-6.	1.6	122
138	Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes and Their Relation to Outcome. American Journal of Cardiology, 2007, 100, 169-174.	1.6	17
139	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal, 2006, 27, 1341-1381.	2.2	1,192
140	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine, 2006, 354, 1464-1476.	27.0	1,104
141	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. Journal of the American College of Cardiology, 2006, 48, 854-906.	2.8	1,044
142	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2006, 151, 654-660.	2.7	101
143	Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2006, 151, 1123-1128.	2.7	78
144	Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial. JAMA - Journal of the American Medical Association, 2006, 295, 1519-1530.	7.4	830

#	Article	IF	CITATIONS
145	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary. European Heart Journal, 2006, 27, 1979-2030.	2.2	612
146	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
147	Magnitude of and Risk Factors for In-Hospital and Postdischarge Stroke in Patients With Acute Coronary Syndromes. Circulation, 2005, 111, 3242-3247.	1.6	93
148	Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. BMJ: British Medical Journal, 2005, 330, 441.	2.3	104
149	Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2005, 150, 1107.e1-1107.e10.	2.7	41
150	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. European Heart Journal, 2004, 25, 166-181.	2.2	334
151	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2004, 291, 2727.	7.4	1,344
152	Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes. Circulation, 2004, 109, 494-499.	1.6	462
153	Acute Coronary Syndromes Without Chest Pain, An Underdiagnosed and Undertreated High-Risk Group. Chest, 2004, 126, 461-469.	0.8	439
154	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, The, 2004, 364, 937-952.	13.7	9,716
155	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2003, 146, 999-1006.	2.7	104
156	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes The Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 2003, 24, 1414-1424.	2.2	225
157	Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. Circulation, 2003, 107, 966-972.	1.6	285
158	Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups. Circulation, 2002, 106, 1622-1626.	1.6	224
159	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet, The, 2002, 359, 373-377.	13.7	496
160	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). American Journal of Cardiology, 2002, 89, 791-796.	1.6	271
161	Stroke in Relation to Cardiac Procedures in Patients With Non–ST-Elevation Acute Coronary Syndrome. Circulation, 2001, 104, 269-274.	1.6	58
162	Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction. Circulation, 2000, 102, 1014-1019.	1.6	688

#	Article	IF	CITATIONS
163	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet, The, 1998, 352, 507-514.	13.7	340